EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets:: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines

The EBV-latent membrane proteins (LMPs) 1 and 2 are among only three viral proteins expressed in EBV-associated Hodgkin's lymphoma and nasopharyngeal carcinoma. Since these tumors are HLA class I and class II-positive, the LMPs could serve as both CD8(+) and CD4(+) T cell targets. In contrast to CD8 responses, very little is known about CD4 responses to LMPs. In this study, we describe CD4(+) T cell clones defining four LNIP1- and three LMP2-derived peptide epitopes and their restricting alleles. All clones produced Th1-like cytokines in response to peptide and most killed peptide-loaded target cells by perforin-mediated lysis. Although clones to different epitopes showed different functional avidities in peptide titration assays, avidity per se was a poor predictor of the ability to recognize naturally infected B lymphoblastoid cell lines (LCLs) expressing LMPs at physiologic levels. Some epitopes, particularly within LMP1, consistently mediated strong LCL recognition detectable in cytokine release, cytotoxicity, and outgrowth inhibition assays. Using cyclosporin A to selectively block cytokine release, we found that CD4(+) T cell cytotoxicity is the key effector of LCL outgrowth control. We therefore infer that cytotoxic CD4(+) T cells to a subset of LMP epitopes could have therapeutic potential against LMP-expressing tumors.